Cardiomyopathy

Cardiomyopathy is disease of the heart muscle itself — not of its arteries or valves, but of the myocardium — in which structural changes reduce how effectively the heart pumps blood. The walls may thicken, stiffen, or dilate depending on the type, and the result is diminished cardiac output that often worsens gradually and silently.

In substance pharmacology, cardiomyopathy appears as an acquired outcome rather than only a pre-existing condition that shapes how an exposure is tolerated. The dilated form is well documented in long-term heavy alcohol use, where ethanol and its metabolite acetaldehyde are thought to cause cumulative damage to heart muscle cells. A stress-induced variant — takotsubo cardiomyopathy — has been described after acute surges of catecholamines, including those triggered by stimulant exposure.

How it is done

Substance-related cardiomyopathy develops through mechanisms that differ by compound and pattern of use. In the alcohol-related form, prolonged heavy exposure is thought to impair energy production within heart muscle cells, disrupt calcium handling, and drive inflammatory and oxidative injury — a process that typically unfolds over years rather than from discrete acute episodes.

In catecholamine-mediated forms, the mechanism is more acute: a sudden large adrenergic surge can cause direct myocyte toxicity and coronary spasm, producing a picture that is sometimes reversible when the trigger is removed. Stimulants associated with high catecholamine release have been implicated in both pathways — acute stress injury in the short term, and structural remodelling with sustained heavy use.

When it matters

Cardiomyopathy becomes acutely urgent when the compensated state breaks down and the heart can no longer maintain adequate output. Signs of acute decompensation include sudden severe breathlessness at rest, inability to lie flat, rapid fluid accumulation in the limbs, and — at the extreme end — low blood pressure and altered consciousness.

Arrhythmias, including atrial fibrillation and ventricular arrhythmias, are also associated with dilated forms and carry their own acute risk independent of pump function. These presentations require emergency medical attention. Known or suspected substance use is relevant clinical history and should be shared with treating clinicians.

What it cannot tell you

The absence of symptoms does not rule out cardiomyopathy. Cardiac function can deteriorate substantially before breathlessness, fatigue, or fluid retention become noticeable, and many cases are identified incidentally on imaging ordered for other reasons. Someone with substance-related cardiomyopathy may feel able to function at a moderate level while the underlying reserve is significantly reduced.

The existence of a partly reversible form — alcoholic cardiomyopathy can show meaningful recovery after cessation — is sometimes taken to imply the damage is always temporary. It is not. Chronic heavy use can progress to irreversible heart failure, and imaging at a single point in time cannot reliably distinguish who is on a recoverable trajectory from who is not.